StudyRareStudyRare

Nonketotic hyperglycinemia (NKH)

Log in to star

Last updated Nov 4, 2026

Log in to add personal notes on this page.

A newborn presents with severe hypotonia, apnea, and intractable seizures within the first days of life. CSF glycine is markedly elevated with an elevated CSF:plasma glycine ratio.

AR; GLDC (P-protein, about 80%) or AMT (T-protein, about 20%) of the glycine cleavage system. Biallelic loss-of-function variants stop glycine breakdown. GCSH (H-protein) has been proposed in two individuals but is unconfirmed.

The glycine cleavage system is a mitochondrial set of proteins that breaks down glycine. The P-protein (GLDC), which carries pyridoxal 5'-phosphate, performs the first step, decarboxylating glycine and releasing CO2. The T-protein (AMT) performs the second, transferring the methyl group from glycine to tetrahydrofolate. The H-protein carries the substrate between them.

Loss of function in either gene lets glycine build up in plasma and, more tellingly, in CSF. Glycine is an allosteric activator of the NMDA receptor, and overstimulation at that glycine site is thought to cause the seizures and developmental impairment. That is the reason for the two treatments: sodium benzoate lowers glycine, and dextromethorphan or ketamine blocks the NMDA receptor.

Residual enzyme activity predicts outcome, and residual activity as low as 1% can give attenuated disease. Two null variants (exon deletions, which are 20% of GLDC variants, or frameshift, nonsense, and canonical splice variants) predict severe NKH; a variant that keeps some activity usually gives attenuated NKH. GLDC and AMT disease look the same clinically.

serine hydroxymethyltransferaseglycine cleavage system,mitochondriaGLDC, AMT; P-protein (carriespyridoxal 5'-phosphate) andT-proteinnonketotic hyperglycinemiaL-serineglycineCO2; methyl groupto tetrahydrofolate
Excerpt from glycine, serine, and proline metabolism. See the full pathway.

Part of glycine, serine, and proline metabolism.

Glycine cleavage, the mitochondrial pathway of glycine degradation.

glycine → glycine cleavage system (the block; P-protein with pyridoxal 5'-phosphate, then T-protein with tetrahydrofolate) → CO2 + methyl group transferred to tetrahydrofolate

  • Accumulates: glycine in plasma and CSF, measured on simultaneous samples; the CSF:plasma glycine ratio rises above normal (0.02 or less).
  • Missing: the breakdown products (CO2 and the methyl group on tetrahydrofolate); the harm comes from excess glycine at NMDA receptors, not from their lack.
  • Severe neonatal encephalopathy
  • Hypotonia, apnea, hiccups
  • Intractable seizures
  • Elevated CSF:plasma glycine ratio (normal 0.02 or less; 0.04 to 0.45 in NKH)
  • Burst suppression on EEG
  • Most severe form: neonatal, lethal
  • Attenuated forms exist
  • Not on standard newborn screening (glycine is not part of routine acylcarnitine/amino-acid profiles flagged for NKH)
  • Elevated plasma and CSF glycine on simultaneous samples with a raised CSF:plasma glycine ratio (normal 0.02 or less; 0.04 to 0.45 in NKH, and a ratio below 0.08 predicts attenuated disease); the CSF glycine level matters more than the ratio
  • Confirm with molecular testing of glycine cleavage system genes (GLDC, AMT, GCSH); exclude secondary causes (e.g., valproate, ketosis)
  • Limited options; sodium benzoate, dextromethorphan, ketogenic diet (variable efficacy)

"NKH is BaD": treatment is sodium Benzoate and Dextromethorphan (an NMDA antagonist that prevents glycine from binding its receptor).

Glycine cleavage system has 3 proteins: P protein (GLDC, ~80% of cases), T protein (AMT, ~20%), and H protein (GCSH, proposed in two individuals, unconfirmed). Glycine builds up in the CSF, causing symptoms.

Reference Links